STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #863 by analyst upside · 2026-08-13
SNDX
Syndax Pharmaceuticals, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+91.5%
implied upside to consensus target
Current Price $19.8
Consensus Target $37.91
Bull Target $57.0
Bear Target $26.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
9
Hold
0
Sell
0
52-Week Low $12.99
52-Week High $25.59
YTD Return -7.0%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.51
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $252M
Profit Margin -87.5%
52-WEEK RANGE
52-Week Low $12.99
52-Week High $25.59
Current Price $19.8
Bear Target $26.0
Bull Target $57.0
● Now $19.8 ● Target $37.91
TRADING DATA
Avg Volume 1.8M
YTD Return -7.0%
Analyst Count 11
Consensus Buy
Upside to Target +91.5%
Last Updated 2026-08-13

ANALYST SUMMARY

Syndax Pharmaceuticals, Inc. (SNDX) is currently trading at $19.8 with a Wall Street consensus price target of $37.91, implying potential upside of 91.5% over the next 12 months. 11 analysts currently cover SNDX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $57.0, while the most cautious has a target of $26.0.

SNDX operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 7.0% year-to-date and is currently trading near the upper end of its 52-week range of $12.99 – $25.59.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SNDX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-06-12 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-05-22 31% win rate (48 calls)
UBS - Reiterated
Buy → Buy 2026-05-13 33% win rate (6 calls)
Barclays - Reiterated
Overweight → Overweight 2026-05-01 Building track record
Goldman Sachs - Reiterated
Buy → Buy 2026-04-01 Building track record
Mizuho - Reiterated
Outperform → Outperform 2026-03-31 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-03-09 43% win rate (7 calls)
Citigroup - Reiterated
Buy → Buy 2026-03-02 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
19/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →